Wasatch Advisors Inc
- SEC CIK
- 0000814133
- Latest filing
- Jul 9, 2026
ESPR holding history
Esperion Therapeutics, Inc. in every 13F filed by Wasatch Advisors Inc, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
ESPR overviewAll 13F holders of ESPRFull Q2 2026 holdings
- Shares (Q2 2026)
- 1,930,185
- Value
- $6.10M
- % of portfolio
- <0.1%
- Quarters held
- 22
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 1,930,185 | $6.10M | <0.1% | −13,838,712−87.8% | Reduced | Holders |
| Q1 2026 | 15,768,897 | $43.2M | 0.3% | +6,323,138+66.9% | Added | Holders |
| Q4 2025 | 9,445,759 | $34.9M | 0.2% | +2,383,902+33.8% | Added | Holders |
| Q3 2025 | 7,061,857 | $18.7M | 0.1% | −3,278,404−31.7% | Reduced | Holders |
| Q2 2025 | 10,340,261 | $10.2M | 0.1% | −590,996−5.4% | Reduced | Holders |
| Q1 2025 | 10,931,257 | $15.7M | 0.1% | −13,551,001−55.4% | Reduced | Holders |
| Q4 2024 | 24,482,258 | $53.9M | 0.3% | +1,136,245+4.9% | Added | Holders |
| Q3 2024 | 23,346,013 | $38.5M | 0.2% | +6,483,070+38.4% | Added | Holders |
| Q2 2024 | 16,862,943 | $37.4M | 0.2% | +7,733,296+84.7% | Added | Holders |
| Q1 2024 | 9,129,647 | $24.5M | 0.1% | +238,544+2.7% | Added | Holders |
| Q4 2023 | 8,891,103 | $26.6M | 0.1% | −2,634,997−22.9% | Reduced | Holders |
| Q3 2023 | 11,526,100 | $11.3M | 0.1% | −1,613,456−12.3% | Reduced | Holders |
| Q2 2023 | 13,139,556 | $18.3M | 0.1% | −214,630−1.6% | Reduced | Holders |
| Q1 2023 | 13,354,186 | $21.2M | 0.1% | +6,505,808+95.0% | Added | Holders |
| Q4 2022 | 6,848,378 | $42.7M | 0.3% | −614,638−8.2% | Reduced | Holders |
| Q3 2022 | 7,463,016 | $50.0M | 0.3% | −82,992−1.1% | Reduced | Holders |
| Q2 2022 | 7,546,008 | $48.0M | 0.3% | −601,372−7.4% | Reduced | Holders |
| Q1 2022 | 8,147,380 | $37.8M | 0.2% | +1,761,117+27.6% | Added | Holders |
| Q4 2021 | 6,386,263 | $31.9M | 0.1% | +3,111,903+95.0% | Added | Holders |
| Q3 2021 | 3,274,360 | $39.5M | 0.2% | −492,575−13.1% | Reduced | Holders |
| Q2 2021 | 3,766,935 | $79.7M | 0.3% | −351,150−8.5% | Reduced | Holders |
| Q1 2021 | 4,118,085 | $115.5M | 0.5% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.